These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 39055561)

  • 1. The investigation of oncolytic viruses in the field of cancer therapy.
    Yuan Z; Zhang Y; Wang X; Wang X; Ren S; He X; Su J; Zheng A; Guo S; Chen Y; Deng S; Wu X; Li M; Du F; Zhao Y; Shen J; Wang Z; Xiao Z
    Front Oncol; 2024; 14():1423143. PubMed ID: 39055561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.
    Jin KT; Du WL; Liu YY; Lan HR; Si JX; Mou XZ
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
    Chen L; Zuo M; Zhou Q; Wang Y
    Front Immunol; 2023; 14():1308890. PubMed ID: 38169820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power Couple.
    Lovatt C; Parker AL
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.
    Zhang Y; Li Y; Chen K; Qian L; Wang P
    Cancer Cell Int; 2021 May; 21(1):262. PubMed ID: 33985527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
    Feola S; Russo S; Ylösmäki E; Cerullo V
    Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Viruses and Cancer Immunotherapy.
    Malhotra J; Kim ES
    Curr Oncol Rep; 2023 Jan; 25(1):19-28. PubMed ID: 36441447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.
    Wang L; Chard Dunmall LS; Cheng Z; Wang Y
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on immunotherapy via oncolytic viruses.
    Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
    Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
    Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R
    Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead.
    Li SJ; Sun ZJ
    Cancer Lett; 2022 Dec; 550():215937. PubMed ID: 36206966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
    Tian Y; Xie D; Yang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
    Hwang JK; Hong J; Yun CO
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.